SERD therapy demonstrates robust anti-proliferative activity in young patients with ER-positive/HER2-negative early breast cancer
Encouraging results with giredestrant support the future use of SERD-based endocrine strategies in this setting
First-in-human trial of a TCR-T therapy targeting KRAS G12V reports a significant response rate
Preliminary results of NW-301V are promising, with a lack of severe adverse effects at all doses tested in patients with pancreatic cancer or colorectal cancer
Next-generation CAR-T cells are in the pipeline
Novel approaches are being tested to overcome current challenges in the use of cellular therapies such as high toxicity and a complex manufacturing process
Novel immunotherapeutics suggest promise in high-grade gliomas
Results from early-phase studies reveal potential for a new cancer vaccine and adaptive immunotherapy
Most women report poor sexual health after a diagnosis of breast cancer
However, patients’ sexual concerns are often unaddressed in oncology, a study suggests
Novel antigens for cancer immunotherapy – a way to enhance effectiveness?
Research is ongoing to revisit the classic neoantigen approach that may better interpret the complexity of the immune system
A study reveals new insights into resistance mechanisms to hormonal therapy in breast cancer
ESR1 variants show to be predictive of response to fulvestrant and novel mutations have been identified
TILs show long-term efficacy in melanoma, but predicting treatment response is still a challenge
After proof of efficacy in patients with melanoma in a clinical trial, major efforts are now directed to make the use of TILs easier and safer in clinical practice.
Improved results from cellular therapies thanks to AI and bioinformatic platforms
Positive signals from early-phase studies suggest that newer molecular technologies may help to disclose the promises of T-cell therapies in different settings
Adoptive cell therapy using TILs shows clinically meaningful and durable efficacy in advanced mucosal melanoma
Antitumour responses were consistent with those previously reported for a broader population of patients with advanced melanoma